NCT02835729View on ClinicalTrials.gov

A Study of Indoximod in Combination With (7+3) Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia

PHASE1CompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

July 31, 2016

Primary Completion Date

October 25, 2019

Study Completion Date

December 27, 2019

Conditions
Acute Myeloid Leukemia
Interventions
DRUG

Idarubicin

Chemotherapy

DRUG

Cytarabine

Chemotherapy

DRUG

Indoximod Freebase

IDO pathway inhibitor

DRUG

Indoximod HCL F1

IDO pathway inhibitor

DRUG

Indoximod HCL F2

IDO pathway inhibitor

Trial Locations (2)

21201

University of Maryland, Baltimore

30912

Augusta University, Augusta

Sponsors
All Listed Sponsors
lead

NewLink Genetics Corporation

INDUSTRY

NCT02835729 - A Study of Indoximod in Combination With (7+3) Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia | Biotech Hunter | Biotech Hunter